PANTHERx® Named Finalist for Specialty Pharmacy 2018 Patient Choice Awards

pantherx zitter health insightsFollowing up on our win in the inaugural Specialty Pharmacy Patient Choice Award last year, PANTHERx® is excited to be recognized for the second consecutive year as a finalist in the Non-PMB/Payer Specialty Pharmacy category for the second annual Patient Choice Awards taking place at Asembia 2018 Specialty Pharmacy Summit.

“This is probably the best part of this Asembia meeting and, quite frankly, our entire year. Satisfaction is the ultimate measure of our success, so our patients are really our primary focus,” remarked Dr. Gordon J. Vanscoy, PANTHERx® Chairman and CEO.

The Patient Choice Awards are presented by Specialty Pharmacy Times (an online and print publication dedicated to the practice of specialty pharmacy) and Zitter Health Insights, a business intelligence firm for specialty pharmacies and other life science focused companies. The awards recognize finalists in two categories – “Pharmacy Benefit Management/Payer Specialty Pharmacy” and “non-Pharmacy Benefit Management/Payer Specialty Pharmacy”.

PANTHERx® Specialty Pharmacy won the inaugural Patient Choice Award in the non-Pharmacy Benefit Management/Payer Specialty Pharmacy category. Finalists are chosen based on their scores in the quarterly Zitter Health Insights Patient Satisfaction Survey. PANTHERx® has followed up its win for the 2016 survey performance with first place finishes in two of the four quarters during this past year.

These awards hold a special significance to PANTHERx®. In our mission to Redefine Care through Uncompromising Quality and Authentic Dedication, PANTHERx® seeks to raise the bar for the quality of care that patients afflicted with rare and complex diseases.

The Specialty Pharmacy 2018 Patient Choice Awards will take place at the 2018 Specialty Pharmacy Summit in Las Vegas on April 30.

https://www.businesswire.com/news/home/20180402005510/en/Specialty-Pharmacy-Times®-Zitter-Health-Insights-Ho

st

Comments are closed.